Gabriele Fischer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gabriele Fischer has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Harald Eder
Drogenambulanz, Klinische Abteilung für Allgemeine Psychiatrie, Universitätsklinik für Psychiatrie, AKH Wien, Germany
4 shared publicationsManfred Weninger
3 shared publications- Reinhold Jagsch
Faculty of Psychology, University of Vienna, Liebiggasse 5, 1010 Vienna, Austria
3 shared publications Alexandra Peternell
2 shared publications- Harald Nikolaus Aschauer
Department of Psychiatry and Psychotherapy, Medical University of VIenna, Vienna, Austria
2 shared publications Martin Langer
2 shared publications
Latest Publications
- 31 August 2001
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 28 (6) , 267-269
Buprenorphin in der Schwangerschaft
Die Behandlung der Opioidabhängigkeit während der Schwangerschaft stellt eine große medizinische Herausforderung dar, da der Konsum von illegalen Substanzen Komplikationen für die schwangere Frau, den Feten und das Neugeborene evozieren kann. Entsprechend dem internationalen Standard ist die Methode der Wahl eine Erhaltungstherapie mit Methadon, die wesentlich zur Stabilisierung der Patientin beiträgt, allerdings in 60 - 80 % ein neonatales Abstinenzsyndrom beim Neugeborenen zur Folge hat, das stärker ausgeprägt und prolongierter verläuft als unter Heroinkonsum der werdenden Mutter. Eine alternative psychopharmakologische Behandlungsmethode stellt die Erhaltungstherapie mit Buprenorphin dar. Es konnte anhand einer Patientin, die seit Jahren ohne Unterbrechung mit Buprenorphin behandelt wird und über den Beobachtungszeitraum von drei Jahren zwei gesunde Kinder bekam, gezeigt werden, dass die kontinuierliche Einnahme von Buprenorphin während der Schwangerschaft in gesunden Kindern resultierte, die auch kein neonatales Abstinenzsyndrom aufwiesen. Der quantitative und qualitative Unterschied des neonatalen Abstinenzsyndroms im Vergleich zu Methadon erklärt sich möglicherweise durch das partielle µ-Rezeptor agonistische und κ-antagonistische Rezeptorprofil von Buprenorphin. The treatment of opioid dependence during pregnancy is a major challenge for doctors, social workers and gynaecologists. Continuous drug abuse during pregnancy can lead to a variety of complications in the mother, fetus and neonate. lt is recommended practice to maintain pregnant opioid-dependent women with synthetic opioids and according to international guidelines, methadone is the recommended substance so far. However, a neonatal abstinence syndrome (NAS) of varying severity is observed in 60 - 80 % of the neonates with even a longer course of duration in comparison to the NAS after heroin consumption during pregnancy. NAS is characterised by tremor, irritability, hypertonicity, vomiting, sneezing, fever, poor suckling, and sometimes convulsions. Recent studies have investigated the safety and efficacy of other synthetic opioids like sublingual buprenorphine for the treatment of pregnant patients. We present a 22 year old opioid-dependent woman, who has been maintained continiously on buprenorphine for 3 years. During the treatment episode she delivered two healthy newborns and both did not show any symptoms of NAS. The maintenance therapy with buprenorphine proved safety and efficacy during pregnancy, the mother was free of continious heroin abuse, verified through supervised urine-toxicology. The quantitative and qualitative difference in NAS may be explained by the partial µ-receptor agonist and κ-antagonist receptor profile of buprenorphine compared to pure µ-agonist action of methadone or heroin.
- 31 August 2001
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 28 (6) , 267-269
Buprenorphin in der Schwangerschaft
Die Behandlung der Opioidabhängigkeit während der Schwangerschaft stellt eine große medizinische Herausforderung dar, da der Konsum von illegalen Substanzen Komplikationen für die schwangere Frau, den Feten und das Neugeborene evozieren kann. Entsprechend dem internationalen Standard ist die Methode der Wahl eine Erhaltungstherapie mit Methadon, die wesentlich zur Stabilisierung der Patientin beiträgt, allerdings in 60 - 80 % ein neonatales Abstinenzsyndrom beim Neugeborenen zur Folge hat, das stärker ausgeprägt und prolongierter verläuft als unter Heroinkonsum der werdenden Mutter. Eine alternative psychopharmakologische Behandlungsmethode stellt die Erhaltungstherapie mit Buprenorphin dar. Es konnte anhand einer Patientin, die seit Jahren ohne Unterbrechung mit Buprenorphin behandelt wird und über den Beobachtungszeitraum von drei Jahren zwei gesunde Kinder bekam, gezeigt werden, dass die kontinuierliche Einnahme von Buprenorphin während der Schwangerschaft in gesunden Kindern resultierte, die auch kein neonatales Abstinenzsyndrom aufwiesen. Der quantitative und qualitative Unterschied des neonatalen Abstinenzsyndroms im Vergleich zu Methadon erklärt sich möglicherweise durch das partielle µ-Rezeptor agonistische und κ-antagonistische Rezeptorprofil von Buprenorphin. The treatment of opioid dependence during pregnancy is a major challenge for doctors, social workers and gynaecologists. Continuous drug abuse during pregnancy can lead to a variety of complications in the mother, fetus and neonate. lt is recommended practice to maintain pregnant opioid-dependent women with synthetic opioids and according to international guidelines, methadone is the recommended substance so far. However, a neonatal abstinence syndrome (NAS) of varying severity is observed in 60 - 80 % of the neonates with even a longer course of duration in comparison to the NAS after heroin consumption during pregnancy. NAS is characterised by tremor, irritability, hypertonicity, vomiting, sneezing, fever, poor suckling, and sometimes convulsions. Recent studies have investigated the safety and efficacy of other synthetic opioids like sublingual buprenorphine for the treatment of pregnant patients. We present a 22 year old opioid-dependent woman, who has been maintained continiously on buprenorphine for 3 years. During the treatment episode she delivered two healthy newborns and both did not show any symptoms of NAS. The maintenance therapy with buprenorphine proved safety and efficacy during pregnancy, the mother was free of continious heroin abuse, verified through supervised urine-toxicology. The quantitative and qualitative difference in NAS may be explained by the partial µ-receptor agonist and κ-antagonist receptor profile of buprenorphine compared to pure µ-agonist action of methadone or heroin.
Treatment of opioid‐dependent pregnant women with buprenorphine
Aims: To assess the maternal and fetal acceptability of buprenorphine and neonatal abstinence syndrome (NAS) in children born to buprenorphine‐maintained mothers. Design and setting: Open‐label, flexible dosing, inpatient induction with outpatient maintenance, conducted at the University of Vienna within the existing pregnancy and drug addiction program. Participants: Fifteen opioid‐dependent pregnant women. Intervention. Sublingual buprenorphine tablets (1‐10 mg/day). Measurements: Mothers: withdrawal symptoms (Wang Scale), nicotine dependence (Fagerstrom Scale: FTQ) and urinalysis. Neonates: birth outcome and NAS (Finnegan Scale). Findings: All subjects were opioid‐, nicotine‐ and cannabis‐dependent. Buprenorphine was well tolerated during induction (Wang Score \< = 4) and illicit opioid use was negligible (91% opioid‐negative). All maternal, fetal and neonatal safety laboratory measures were within normal limits or not of clinical significance. Mean birth outcome measures including gestational age at delivery (39.6 ± 1.5 weeks), Apgar scores (1 min = 8.9; 5 min = 9.9; and 10 min = 10), birth weight (3049 ± 346 g), length (49.8 ± 1.9 cm) and head circumference (34.1 ± 1.8 cm) were within normal limits. The NAS was absent, mild (without treatment) and moderate (with treatment) in eight, four and three neonates, respectively. The mean duration of NAS was 1.1 days. Conclusions: Buprenorphine appears to be well accepted by mother and fetus, and associated with a low incidence of NAS. Further investigation of buprenorphine as a maintenance agent for opioid‐dependent pregnant women is needed.
Treatment of opioid‐dependent pregnant women with buprenorphine
Aims: To assess the maternal and fetal acceptability of buprenorphine and neonatal abstinence syndrome (NAS) in children born to buprenorphine‐maintained mothers. Design and setting: Open‐label, flexible dosing, inpatient induction with outpatient maintenance, conducted at the University of Vienna within the existing pregnancy and drug addiction program. Participants: Fifteen opioid‐dependent pregnant women. Intervention. Sublingual buprenorphine tablets (1‐10 mg/day). Measurements: Mothers: withdrawal symptoms (Wang Scale), nicotine dependence (Fagerstrom Scale: FTQ) and urinalysis. Neonates: birth outcome and NAS (Finnegan Scale). Findings: All subjects were opioid‐, nicotine‐ and cannabis‐dependent. Buprenorphine was well tolerated during induction (Wang Score \< = 4) and illicit opioid use was negligible (91% opioid‐negative). All maternal, fetal and neonatal safety laboratory measures were within normal limits or not of clinical significance. Mean birth outcome measures including gestational age at delivery (39.6 ± 1.5 weeks), Apgar scores (1 min = 8.9; 5 min = 9.9; and 10 min = 10), birth weight (3049 ± 346 g), length (49.8 ± 1.9 cm) and head circumference (34.1 ± 1.8 cm) were within normal limits. The NAS was absent, mild (without treatment) and moderate (with treatment) in eight, four and three neonates, respectively. The mean duration of NAS was 1.1 days. Conclusions: Buprenorphine appears to be well accepted by mother and fetus, and associated with a low incidence of NAS. Further investigation of buprenorphine as a maintenance agent for opioid‐dependent pregnant women is needed.
Comparison of methadone and slow‐release morphine maintenance in pregnant addicts
Aims. To investigate whether the neonatal abstinence syndrome (NAS) is different in children born to women maintained on slow‐release morphine, compared with those maintained on methadone, and to compare additional drug consumption in these groups of women . Design, Setting and Participants. An open, randomized trial was conducted in an established clinic. Forty‐eight pregnant women who presented to the clinic as opiate or polysubstance abusers were enrolled and maintained on either methadone (24 women) or slow‐release morphine (24 women) up to and following delivery. The programme included psychosocial therapy and support for their opiate‐addicted partners . Measurements. Standard urinalysis methods were used to measure consumption of cocaine and benzodiazepines during pregnancy. Injection sites were monitored to indicate additional opiate use. NAS was measured according to Finnegan score and the amount of phenobarbiturates prescribed to alleviate the symptoms . Findings. No difference was found in the number of days that NAS was experienced by neonates born to methadone or morphine maintained mothers (mean = 16 and 21 days, respectively). All children were born healthy and no serious complications arose. Fewer benzodiazepines ( p 0.05) and fewer additional opiates ( p 0.05) were consumed by the morphinemaintained women compared with those who took methadone, but no difference was seen in cocaine consumption. Nicotine consumption was reduced significantly in both groups during pregnancy ( p 0.02) . Conclusions. Both methadone and morphine are suitable maintenance agents for pregnant opiate addicts. Maintenance agents that result in a less prolonged NAS should be studied in further trials.
Comparison of methadone and slow‐release morphine maintenance in pregnant addicts
Aims. To investigate whether the neonatal abstinence syndrome (NAS) is different in children born to women maintained on slow‐release morphine, compared with those maintained on methadone, and to compare additional drug consumption in these groups of women . Design, Setting and Participants. An open, randomized trial was conducted in an established clinic. Forty‐eight pregnant women who presented to the clinic as opiate or polysubstance abusers were enrolled and maintained on either methadone (24 women) or slow‐release morphine (24 women) up to and following delivery. The programme included psychosocial therapy and support for their opiate‐addicted partners . Measurements. Standard urinalysis methods were used to measure consumption of cocaine and benzodiazepines during pregnancy. Injection sites were monitored to indicate additional opiate use. NAS was measured according to Finnegan score and the amount of phenobarbiturates prescribed to alleviate the symptoms . Findings. No difference was found in the number of days that NAS was experienced by neonates born to methadone or morphine maintained mothers (mean = 16 and 21 days, respectively). All children were born healthy and no serious complications arose. Fewer benzodiazepines ( p 0.05) and fewer additional opiates ( p 0.05) were consumed by the morphinemaintained women compared with those who took methadone, but no difference was seen in cocaine consumption. Nicotine consumption was reduced significantly in both groups during pregnancy ( p 0.02) . Conclusions. Both methadone and morphine are suitable maintenance agents for pregnant opiate addicts. Maintenance agents that result in a less prolonged NAS should be studied in further trials.
- 1 January 1999
- Vol. 149 (11) , 331-6
[Interdisciplinary therapeutic approaches with substance abusers taking into consideration gender differences].
Scientific advances over the past 20 years have shown that drug addiction is a chronic, relapsing disease that results from the prolonged effects of drugs on the brain. As with many other brain diseases, addiction includes behavioral and social-context aspects that are important parts of the disorder itself. Therefore, the most effective treatment approaches will include biological, behavioral and social-context components. Whereas the basic treatment approach in substance dependence involves the medical field, psychosocial support is the second main area which has to be included in order to gain a successful treatment outcome. In addition, psychotherapy presents a third useful area in the field of the treatment of drug addiction, but only under the consideration that the addict shows a continuing motivation to change. Recognizing addiction as a chronic, relapsing brain disorder characterized by compulsive drug seeking and use can impinge on society's overall health and social policy strategies and help diminish the health and social costs associated with drug abuse and addiction. Treatment of substance dependence in men differs from treatment of substance dependence in women; drug addiction in females requires special attention when the woman is pregnant.
- 1 January 1999
- Vol. 149 (11) , 331-6
[Interdisciplinary therapeutic approaches with substance abusers taking into consideration gender differences].
Scientific advances over the past 20 years have shown that drug addiction is a chronic, relapsing disease that results from the prolonged effects of drugs on the brain. As with many other brain diseases, addiction includes behavioral and social-context aspects that are important parts of the disorder itself. Therefore, the most effective treatment approaches will include biological, behavioral and social-context components. Whereas the basic treatment approach in substance dependence involves the medical field, psychosocial support is the second main area which has to be included in order to gain a successful treatment outcome. In addition, psychotherapy presents a third useful area in the field of the treatment of drug addiction, but only under the consideration that the addict shows a continuing motivation to change. Recognizing addiction as a chronic, relapsing brain disorder characterized by compulsive drug seeking and use can impinge on society's overall health and social policy strategies and help diminish the health and social costs associated with drug abuse and addiction. Treatment of substance dependence in men differs from treatment of substance dependence in women; drug addiction in females requires special attention when the woman is pregnant.
- 1 October 1998
- Published by S. Karger AG in European Addiction Research
- Vol. 4 (Suppl. 1) , 32-36
Buprenorphine Maintenance in Pregnant Opiate Addicts
Opioid maintenance agents such as methadone and slow-release morphine have provided beneficial effects in pregnant opioid-dependent women in both themselves and their child. However, one of the major drawbacks involved with these agents is that they cause an increase in the severity of neonatal abstinence syndrome (NAS) when compared to mothers using heroin. Consequently, a trial was performed to investigate the effects of buprenorphine use during pregnancy. A total of nine pregnant opioid-dependent women were transferred from either a mean daily dose of 39.7 mg methadone or 400 mg slow-release morphine to a mean daily dose of 8.1 mg buprenorphine. The buprenorphine-maintained patients were integrated into an already established outpatient maintenance treatment programme covering all aspects of prenatal and perinatal care. Results demonstrated that buprenorphine administration in opioid-dependent pregnant patients is efficacious and well tolerated. Babies born to buprenorphine-maintained patients had birthweight and Apgar scores within the normal range (2,500–4,500 g and 9–10, respectively) and no evidence of opioid-related NAS was observed. The results from this preliminary study indicate the potential for buprenorphine maintenance therapy in pregnant addicts, although further research is required to confirm this hypothesis.
- 1 October 1998
- Published by S. Karger AG in European Addiction Research
- Vol. 4 (Suppl. 1) , 32-36
Buprenorphine Maintenance in Pregnant Opiate Addicts
Opioid maintenance agents such as methadone and slow-release morphine have provided beneficial effects in pregnant opioid-dependent women in both themselves and their child. However, one of the major drawbacks involved with these agents is that they cause an increase in the severity of neonatal abstinence syndrome (NAS) when compared to mothers using heroin. Consequently, a trial was performed to investigate the effects of buprenorphine use during pregnancy. A total of nine pregnant opioid-dependent women were transferred from either a mean daily dose of 39.7 mg methadone or 400 mg slow-release morphine to a mean daily dose of 8.1 mg buprenorphine. The buprenorphine-maintained patients were integrated into an already established outpatient maintenance treatment programme covering all aspects of prenatal and perinatal care. Results demonstrated that buprenorphine administration in opioid-dependent pregnant patients is efficacious and well tolerated. Babies born to buprenorphine-maintained patients had birthweight and Apgar scores within the normal range (2,500–4,500 g and 9–10, respectively) and no evidence of opioid-related NAS was observed. The results from this preliminary study indicate the potential for buprenorphine maintenance therapy in pregnant addicts, although further research is required to confirm this hypothesis.